FBL4 Inhibitors

Chemical inhibitors of FBL4 function by targeting various components of the ubiquitin-proteasome system, which is integral to the protein's role in ubiquitination and subsequent proteasomal degradation of target proteins. MG132, Bortezomib, and Lactacystin are proteasome inhibitors that prevent the breakdown of polyubiquitinated proteins. By blocking the proteasome's function, these inhibitors can maintain the ubiquitinated proteins in an undegraded state, thus indirectly inhibiting the role of FBL4 in facilitating their degradation. MG132 acts non-selectively, while Bortezomib specifically targets the 26S proteasome, and Lactacystin operates by a similar mechanism but is distinguished by its irreversible binding to the proteasome. Clasto-Lactacystin β-lactone, a derivative of Lactacystin, and Epoxomicin, another selective proteasome inhibitor, function in a comparable manner, ensuring that the proteins, which FBL4 has marked for degradation, remain undegraded, accumulating within the cell. Continuing with the theme of proteasome inhibition, Carfilzomib and Oprozomib, like Bortezomib and its alternative name Velcade, lead to the inhibition of the proteasome function, further stabilizing the proteins that FBL4 targets for degradation. On the other hand, MLN4924 (Pevonedistat) inhibits the NEDD8-activating enzyme. Since NEDDylation is essential for the activity of Cullin-RING E3 ubiquitin ligases, of which FBL4 is a part, MLN4924 can indirectly inhibit FBL4's function by preventing its activation. PYR-41 targets the E1 ubiquitin-activating enzyme, reducing the ubiquitination process at its earliest stage, which would reduce the substrate availability for FBL4-mediated ubiquitination. IU1 inhibits USP14, a deubiquitinase that can increase ubiquitin recycling, thereby disturbing the ubiquitin balance and potentially inhibiting FBL4's action by altering the ubiquitin pool availability. Lastly, Filastatin, by preventing protein aggregation, may influence the turnover rates of proteins and indirectly affect the ubiquitination process that FBL4 is involved in, leading to an inhibition of its function within the cell.